Modern treatment of metastatic triple-negative breast cancer

For many years chemotherapy was the only treatment option for metastatic triple-negative breast cancer (TNBC). The most recent therapeutic options now include immunotherapy with checkpoint inhibitors. Based on the IMpassion130 trial the checkpoint inhibitor atezolizumab is approved for first-line treatment in combination with nab-paclitaxel when the PDL1 status is positive. In the presence of proven BRCA mutation, the poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors olaparib and talazoparib are additional treatment options both in triple-negative and hormone receptor positive Her2 negative metastatic breast cancer. Further promising drugs, such as AKT inhibitors and the antibody-drug conjugate sacituzumab govitecan are currently being investigated in clinical trials. © 2020, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.